YC-1 3- 5-Hydroxymethyl-2-furyl -l-benzyl indazole

BAY 41-2272 is a novel non-NO-based soluble GC activator. It produced a marked inhibition of platelet aggregation in washed platelets and PRP, however, with much lower potency in PRP. Both NO and prostacyclin exhibited synergistic activity with BAY 41-2272 to inhibit platelet aggregation. In vivo, BAY 41-2272 significantly reduced blood pressure in rats, but it had only a small effect on FeCl3-induced thrombosis [107]. 

PK [108]. Therefore the use of such substances for platelets requires exact monitoring of their effects, e.g. by controlling phosphorylation of cGMP-PK substrate proteins. 

---